<DOC>
	<DOC>NCT00134498</DOC>
	<brief_summary>The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.</brief_summary>
	<brief_title>A Study Comparing The Efficacy &amp; Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides</brief_title>
	<detailed_description>For additional information please call: 1-800-718-1021</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type IV</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<criteria>Diagnosis of Fredrickson Type IV Hypertriglyceridemia Women who are pregnant or lactating, or planning to become pregnant. Subjects with a clinically indicated need for statin (HMGCoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDLC and HDLC including fibrates and nicotinic acid Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMGCoA reductase inhibitors Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>